- Home
- Companies
- Abram Scientific, Inc.
- Applications
- Vitro Diagnostic System for COVID-19 ...
Vitro Diagnostic System for COVID-19 Patients - Medical / Health Care
A high incidence of thromboembolic complications leading to organ-failure, stroke, pulmonary embolism (PE) and deep vein thrombosis (DVT) have been reported in asymptomatic, symptomatic, and recovering patient groups.
Coagulopathy is a major cause of death in COVID-19 patients
-
Coagulopathy plays a crucial role in the initial development of respiratory symptoms in COVID-19 patients and monitoring could predict disease progression.
-
Anticoagulation and transfusion therapies and monitoring are crucially needed both in inpatient and outpatient settings to ensure survival.
Viscoelastic tests can accurately detect and manage Coagulopathy
-
Consensus guidelines published by physicians and surgeons from the pandemic frontline in Wuhan specifically recommends the routine use of viscoelastic tests for diagnosing the type and extent of coagulopathy in COVID-19 patients.
-
Viscoelastic tests are increasingly being used as the ideal go-to-solution to screen for and accurately diagnose the hypercoagulable state observed in COVID-19 patients (i.e. by measuring clot stiffness & lysis) and enable goal-directed anticoagulation and blood transfusion management.
Critical need for fast, point-of-care (POC) viscoelastic tests to:
-
Quickly screen for coagulopathy in asymptomatic and symptomatic COVID-19 patients.
-
Provide closed-loop therapeutic management in ambulatory, inpatient and outpatient settings.